David Raiser is the CEO and co-founder of Aldatu Biosciences, a company that has developed drug resistance diagnostics for HIV patients.

Raiser holds a Ph.D. in Genetics from Harvard Medical School, while his co-founder and Aldatu's CSO Iain MacLeod has a plethora of degrees — including a Ph.D. in Pathology from the University of Cambridge— as well as an academic appointment at the Harvard School of Public Health AIDS Initiative. Together, the pair is leading a push for better, more affordable diagnostics tools, not only for HIV-related applications but also for other infectious diseases, in order to improve the quality of patient care and the cost of healthcare.